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Abstract
Cancer from smoking tobacco is considered dependent on mutagens, but significant molecular aspects of smoking-specific, cancer development remain
unknown. We defined sets of coding regions for oncoproteins, tumor suppressor proteins, and cytoskeletal-related proteins that were compared between
nonsmokers and smokers, for mutation occurrences, in the lung adenocarcinoma (LUAD), head and neck squamous carcinoma (HNSC), bladder carcinoma (BLCA), and pancreatic adenocarcinoma ( PAAD) datasets from the
cancer genome atlas (TCGA). We uncovered significant differences in overall
mutation rates, and in mutation rates in cytoskeletal protein-related coding
regions (CPCRs, including extracellular matrix protein coding regions),
between nonsmokers and smokers in LUAD and HNSC (P < 0.001), raising
the question of whether the CPCR mutation differences lead to different clinical courses for nonsmoker and smoker cancers. Another important question
inspired by these results is, whether high smoker cancer mutation rates would
facilitate genotoxicity or neoantigen-based therapies. No significant, mutationbased differences were found in the BLCA or PAAD datasets, between nonsmokers and smokers. However, a significant difference was uncovered for the
average number of overall cancer mutations, in LUAD, for persons who
stopped smoking more than 15 years ago, compared with more recent smokers (P < 0.032).

Introduction
Tobacco use has long been associated with increased incidence of lung (Kasala et al. 2015), head and neck (Hayes
et al. 2015), pancreatic (Maisonneuve and Lowenfels 2015)
and bladder cancer (Cumberbatch et al. 2016), but the
mechanisms of cancer initiation and progression dependent
on tobacco use are not comprehensively understood. In
particular, mutations caused by smoke-related mutagens
are considered an important cause (Kim et al. 1993), but
other factors, such as smoking dependent, reduced CpG
island methylation, could also play a role (Klingbeil et al.

2014; Philibert et al. 2014). We grouped nonsmokers and
smokers using the TCGA clinical files and compared their
mutation occurrences. The analysis of the data below indicates that recognized cancer driver mutations in lung adenocarcinoma distinguish nonsmokers from smokers but
not in head and neck, bladder or pancreatic cancer. In bladder cancer, in particular, our analysis indicates that lower
methylation (and thereby reduced suppression) of oncogenes in smokers may be the distinguishing factor between
nonsmoker- and smoker-related disease.
Cytoskeletal proteins are emerging as a distinct class of
cancer driver proteins, particularly in view of their likely
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capacity for function as dominant-negative drivers (Fawcett et al. 2015; Parry et al. 2015; Parry and Blanck 2016),
in that mutations in any one of many places in the coding region of a filamentous protein would have the
impact of disrupting polymer formation, as happens with
any number of mutations in the coding regions for the
collagen subunits that form collagen molecules and cartilage. In addition, cytoskeletal-related protein coding
regions (CPCRs), including extracellular matrix (ECM)
protein coding regions, occupy a relatively large genomic
space. For example, the CPCR set that is among the top
25 most mutated coding regions among 10 cancer datasets represents about 15% of all of the human coding
regions (Parry and Blanck 2016). Thus, this CPCR set has
great potential as a biomarker of mutagenesis. This is particularly true keeping in mind the many reagents and
processes available to assess cytoskeletal and ECM integrity and the fact that a disorganized cytoskeleton has been
long associated with tumorigeneis (Verderame et al.
1980). Thus, this report includes an assessment of mutation rates for this previously established, cancer-relevant
CPCR set.

Methods
Clinical and somatic mutation data (BI_Illumina) were
downloaded for the lung adenocarcinoma (LUAD), head
and neck squamous carcinoma (HNSC), bladder carcinoma (BLCA), and PAAD datasets from the TCGA data
portal (http://cancergenome.nih.gov/), following NIH
approval (request #27073-3 for project #6300). The clinical patient file was used to sort barcodes into lifelong
nonsmokers and smokers for each cancer dataset. Tumor
sample barcodes in the somatic mutation file were truncated to contain only the following characters, TCGA-######. A cancer file, for example, “SOM, LUAD results”,
was created for each cancer set. The truncated tumor
sample barcodes along with the nonsmoker and smoker
barcodes were then copied into the total mutations sheet
of each cancer file. A COUNTIF function was used to
determine the total number of mutations for each barcode in both the nonsmoking and smoking categories.
Barcodes in nonsmoker and smoker categories, respectively, that did not appear in the mutation file were eliminated. The final lists of nonsmoker and smoker barcodes
representing mutations were determined. The nonsmoking and smoking barcodes were then compared based on
their total mutation frequencies.
Three sets of coding regions, for analysis of mutation
occurrence between nonsmoker and smoker categories,
were established: (1) cytoskeletal protein-related coding
regions (CPCRs) (Fawcett et al. 2015; Parry and Blanck
2016; Parry et al. 2015); (2) oncoprotein (Fawcett et al.
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2015; Parry et al. 2015); (3) tumor suppressor proteins
(Fawcett et al. 2015; Parry et al. 2015). The CPCRs were
previously determine in ref. (Parry et al. 2015), based on
their occurrence in the top 25 most commonly mutated
coding regions among the five TCGA datasets studied in
ref. (Parry et al. 2015) (BLCA, COAD, LUAD, GBM,
STAD). Three additional CPCRs were added to the set
indicated in the preceding sentence, representing commonly mutated CPCRs in the SKCM dataset. The HUGO
symbols for the coding regions for all sets are in Table 1.
Within each cancer file (e.g., “SOM, LUAD results”), a
sheet for total mutations, including only the original barcodes truncated as indicated above and two sheets for
each coding region set, for example, “CPCR Mut.” and
“CPCR Results,” were created. The coding region mutation sheet includes information from the comprehensive
mutation file, such as HUGO symbol, truncated tumor
sample barcode, and mutation type (amino acid altering
or silent). The list of nonsmoker and smoker barcodes
was compared to the comprehensive mutation data using
a COUNTIF function (in the coding region mutation
sheet) to determine the number of mutations per barcode. The coding region mutations of nonsmokers and
smokers were compared in the “results” sheet.

Table 1. HUGO symbols for the CPCR, oncoprotein, and tumor
suppressor protein gene sets (detailed in the SOM file labeled,
“SOM Table 1, source file”).
Gene set
Cytoskeletal
ANK2
APC
COL11A1
DNAH10
DNAH11
DNAH3
DNAH5
DNAH7
DNAH8
DSCAM
DST
FAT3
FAT4
FBN2
FLG
GPR98
MUC16
MUC17

Oncoprotein
MUC4
NEB
NEFH
NF1
PCDH15
PCDHAC2
PCDHGC5
PCLO
PKHD1
PLEC
RELN
SPTA1
SPTAN1
SSPO
SYNE1
SYNE2
TTN
XIRP2

ACVR1
ALK
ARAF
BRAF
CTNNB1
EGFR
FGFR2
FLT3
FRK
HRAS
JAK2
KRAS
MTOR
NRAS
PRKACA
RAF1

Tumor suppressor
AKAP12
AXIN1
BMP2
BMPR1B
BMPR2
BRCA1
BRCA2
BRMS1
CASZ1
CDKN2A
CHD5
CHEK2
CTCF
DLC1
DOK2
FLCN
FOXP3
GPR68
ING1
ING4
INPP4B
KISS1

KISS1R
KLF6
LATS2
LIMD1
MAP2K4
MED23
PBRM1
PEBP1
PPAPDC1B
PRDM2
PTEN
RB1
RECK
SMAD4
SMAD7
SMARCB1
SP100
TFPI2
TMPRSS11A
TXNIP
VHL
WWOX

CPCR, cytoskeletal protein-related coding regions.
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From the LUAD clinical patient file, available data on
the years started and stopped smoking were collected
(“SOM Table 2, source file”). Groups of (1) less than or
equal to, (2) greater than 15 years from the time of
smoking cessation, (3) less than or equal to, and (4)
greater than 30 years of total years of smoking were
established and then compared based on the number of
total mutations per barcode.
The number of deleterious amino acid changes was
determined using PROVEAN. The chromosome number,
start position, reference allele, and tumor sequence allele
for the CPCR and tumor suppressor datasets for nonsmokers and smokers in each cancer were copied and pasted
into PROVEAN under the Human Genome Variants protocol. The removal of duplicates from the “#ROW_NO.”
column in the PROVEAN output was used to determine
the number of deleterious amino acid changes for the
CPCR and tumor suppressor datasets. The total was then
divided by the sample size to determine the average number of deleterious amino acid changes for nonsmokers and
smokers in each cancer set. (An example with additional
detail is provided in the SOM file labeled, “SOM Example
Deleterious AA, LUAD CPCR”).
Level 3 JHU-USC HumanMethylation450 data for the
top five available barcodes with the highest mutation burdens for nonsmokers and smokers of each cancer set were
downloaded from the TCGA data portal. Average beta
values for the entire methylation file and oncoprotein
datasets were determined for each barcode (“SOM
Table 4, source file”).

Results
The TCGA datasets of LUAD, HNSC, BLCA, and PAAD
were compared based on mutation frequencies between

lifelong nonsmokers and smokers. The total number of
mutations per barcode was calculated, and the average
number of mutations per barcode was determined for
nonsmokers and smokers for each cancer type (Fig. 1).
The overall mutation rates for LUAD and HNSC, distinguishing nonsmokers and smokers, were found to be statistically significant, however, no such distinction could
be established for the BLCA and PAAD datasets.
Next, three cancer driver gene subsets (Fawcett et al.
2015; Parry et al. 2015) were established for analysis: (1)
CPCRs; (2) oncoprotein; (3) tumor suppressor proteins
(Table 1). Mutation frequencies were evaluated for nonsmokers and smokers for each gene set for the four cancer
types. Smokers had a significantly higher average mutation
rate for all three coding region sets for LUAD (Fig. 2); and
smokers had a significantly higher number of mutations for
the CPCR gene set in HNSC (Fig. 3), reflecting the HNSC
results for the overall mutation rates and the distinction
between nonsmokers and smokers (Fig. 1). Mutations rates
of the remaining gene sets for HNSC (oncoprotein and
tumor suppressor protein) failed to distinguish nonsmokers and smokers in the indicated analyses. None of the gene
set mutation rates distinguished nonsmokers from smokers
for the BLCA and PAAD datasets.
To further emphasize the distinction in mutation rates,
between nonsmokers and smokers, for LUAD and HNSC,
the 25 barcodes with the highest mutation frequency and
the 25 barcodes with the lowest mutation frequency were
compared based on their inclusion in the nonsmoker or
smoker groups (detailed in the SOM files labeled, “SOM,
LUAD results” and “SOM, HNSC results”). In both cases,
the high-frequency mutation groups were dominated by
smoker barcodes (LUAD P < 2E-12, HNSC P < 6E-8) and
the low-frequency mutation groups were about evenly
distributed between nonsmokers and smokers.

Table 2. Comparison of available data from the LUAD dataset based on the year started and stopped smoking (detailed in the SOM file
labeled, “SOM Table 2, source file”).
Number of years since
stopped smoking
(≤15 years vs. >15 years)
P-value for ≤15 years
versus >15 years
since stopped
smoking
Avg number of
mutations/barcode
for ≤15 years
Avg number of
mutations/barcode
for >15 years

0.0315

Total number of years
smoked (≤30 years
vs. >30 years)
P-value for ≤30 years
versus >30 years of smoking

0.9148

604.06

Avg number of mutations/
barcode for >30 years

493.11

387.65

Avg number of mutations/
barcode for ≤30 years

482.55

LUAD, lung adenocarcinoma.
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Figure 1. Average number of total mutations per barcode for
nonsmokers versus smokers for each cancer type. *indicates
P < 0.001 (LUAD P = 1.16e-18) (HNSC P = 0.00057) (BLCA and
PAAD P > 0.05 not significant) (detailed in the SOM file labeled,
“SOM Figs. 1 and 2, source file”). Demographic information for all
four of the indicated cancer datasets: Gender, race, and age were
recovered from the TCGA clinical files for the LUAD, HNSC, BLCA,
and PAAD cancer sets for nonsmokers and smokers (detailed and
summarized in distinct sheets of the Excel SOM file labeled, “SOM
Demographics”). There were no significant differences in the age
ranges for nonsmokers versus smokers in any of the cancer sets.
The vast majority of the subjects were white, and no conclusions
can be drawn from the race/ethnicity groupings. Finally, there was
a slight skewing of more males, on a percentage basis, who were
smokers, for each cancer dataset, but again, the differences were
not sufficient for a statistical analysis. BLCA, bladder carcinoma;
PAAD, pancreatic adenocarcinoma.

16.00

Average number of mutations per barcode for each gene set in LUAD
Nonsmokers
Smokers

Average # of mutations

14.00
12.00
10.00
8.00
6.00
4.00
2.00
0.00

CPCR

Oncoprotein

Tumor supressor

Gene set
Figure 2. Average number of mutations per barcode for each
gene set in LUAD for nonsmokers versus smokers. All gene sets
have P < 0.001 (detailed in the SOM file labeled, “SOM Figure 1
and 2, source file”).

Public health data have strongly indicated, for decades,
that smoking cessation is accompanied by a reduced risk
of cancer and the results continue to be confirmed with
recent work (Wynder and Hoffmann 1976; Wynder and
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Stellman 1977; Ogihara et al. 2016). However, possible
molecular explanations for this phenomenon have been
limited (Wang et al. 1999), usually to specific genes. We
found that groups of (1) less than or equal to, and (2)
greater than 15 years since smoking cessation had a significant difference in the number of mutations per barcode. Barcode groups of (3) less than or equal to, and
(4) greater than 30 years of total years smoked had no
difference (Table 2), indicating that the significant difference in the number of mutations between the smoking
and smoking-cessation groups was not simply due to
fewer years smoked among the smoking-cessation group.
To further address this (trivial) possibility, we examined
the distribution of the total number of years smoked in
all of the above-indicated sets, and it is clear that the
smoking and smoking cessation groups have a much larger overlap of years smoked than do the two groups
based on total number of years smoked (Fig. 4). This
strongly indicates that the significant difference in the
number of mutations between the smoking and smoking-cessation groups is not due to a difference in the
number of mutations accumulating on a per-year basis.
If that were the case, the difference in the number of
mutations distinguishing the “over 30 years” and under
30 years groups would likely be significant, that is, parallel to the average number of years smoked. (In this latter
case, the average number of years smoked is dramatically
different based on the distributions of years smoked
(Fig. 4B), but the number of mutations in the cancer
samples is not (Table 2).)
To address whether the higher smoker mutation rates
could have an impact on cellular function, the number of
deleterious amino acid changes for the CPCR and tumor
suppressor datasets were also considered (Table 3). The
LUAD dataset had the largest average number of deleterious amino acid changes per barcode, as well as, the greatest difference between nonsmokers and smokers in both
the CPCR and tumor suppressor datasets, consistent with
the above distinctions between nonsmokers and smokers
based on mutations alone.
Data indicated that both BLCA and PAAD development are associated with smoking. Likewise, HNSC has
been linked to smoking. Yet, in none of these cases were
we able to observe oncoprotein or tumor suppressor protein mutation increases among the smokers. There are
numerous possible explanations for this, not the least of
which is that the difference between nonsmokers and
smokers is related to incidence of occurrence of a “single
hit” basis for the cancers and not due to any “amplification” requirement that could be traceable to an increased
number of mutations. Nevertheless, the increased number
of mutations in cancer driver coding regions in the
LUAD dataset raises the question of whether nonsmokers
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Figure 3. (A) Normal distribution of total mutations per barcode in LUAD for nonsmokers versus smokers. (P < 1.0e-17) (detailed in the SOM
file labeled, “SOM, LUAD results”). (B) Normal distribution of total mutations per barcode in HNSC for nonsmokers versus smokers.
(P < 0.0006) (detailed in the SOM file labeled, “SOM, HNSC results”). (C) Normal distribution of CPCR mutations per barcode in LUAD for
nonsmokers versus smokers. (P < 1.3e-20) (detailed in the SOM file labeled, “SOM, LUAD results”). (D) Normal distribution of CPCR mutations
per barcode in HNSC for nonsmokers versus smokers. (P < 1.5e-7) (detailed in the SOM file labeled, “SOM, HNSC results”). (E) Normal
distribution of CPCR mutations per barcode in BLCA for nonsmokers versus smokers. (P > 0.05 not significant) (detailed in the SOM file
labeled, “SOM, BLCA results”). (F) Normal distribution of CPCR mutations per barcode in PAAD for nonsmokers versus smokers. (P > 0.05 not
significant) (detailed in the SOM file labeled, “SOM, PAAD results”). CPCR, cytoskeletal protein-related coding regions; HNSC, head and neck
squamous carcinoma; LUAD, lung adenocarcinoma; PAAD, pancreatic adenocarcinoma.
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Figure 4. (A) Normal distributions for the total years smoked between the ≤15 years since quitting and >15 years since quitting smoking
groups (detailed in the SOM file labeled, “SOM Table 2, source file”). (B) Normal distributions of total years smoked between the ≥30 years
and <30 years of total years smoking (detailed in the SOM file labeled, “SOM Table 2, source file”). BLCA, bladder carcinoma; HNSC, head and
neck squamous carcinoma.

could be distinguished from smokers via another molecular attribute related to cancer development.
Thus, we considered the possibility that nonsmokers
and smokers could be distinguished on the basis of
reduced methylation of oncoprotein coding regions, presumably leading to a relative upregulation of oncoprotein
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expression. Indeed, there have been reports linking smoking chemicals to interference in CpG island methylation
(Klingbeil et al. 2014; Philibert et al. 2014; Bjaanaes et al.
2016). Thus, we compared the methylation averages for
the top five available barcodes with the highest mutation
burdens for nonsmokers and smokers in each cancer set
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Table 3. Average number of deleterious mutations per barcode in the CPCR and tumor suppressor data sets for all four cancer sets (detailed
in the SOM file labeled, “SOM Table 3, source file” and additional information for the method is detailed in the SOM file labeled, “SOM
Example Deleterious AA, LUAD CPCR”).
LUAD

Avg # of deleterious CPCR mut/barcode
Avg # of deleterious tumor suppressor
mut/barcode

HNSC

BLCA

PAAD

Smokers

Nonsmokers

Smokers

Nonsmokers

Smokers

Nonsmokers

Smokers

Nonsmokers

4.43
0.52

0.86
0.15

2.28
0.45

0.90
0.36

2.15
0.37

1.83
0.50

0.19
0.09

0.19
0.06

BLCA, bladder carcinoma; CPCR, cytoskeletal protein-related coding regions; HNSC, head and neck squamous carcinoma; LUAD, lung adenocarcinoma; PAAD, pancreatic adenocarcinoma.

(Table 4). We selected the barcodes with the highest
numbers of mutations to effect the premise that, in
demonstrating a nonmutation possibility for the mechanism of the smoking impact, the highest standard would
be such a demonstration where samples had many mutations. This is in contrast to a comparison of samples with
few or no mutations (e.g., no mutations in oncoproteins)
where a second mechanism must be in effect. In other
words, a second mechanism should be identifiable above
a relatively high background of mutations, because for
certain gene sets and cancer datasets, detailed above,
mutation rates do not distinguish nonsmokers from
smokers.
We found the BLCA cancer set had a significantly
reduced level of methylation for smokers, in comparison
with nonsmokers for both the average, overall genome
methylation, and the average methylation of the genes for
the oncoprotein set used above and defined in refs. (Fawcett et al. 2015; Parry et al. 2015) (P < 0.0085 and
P < 0.011, respectively). The PAAD dataset also showed a
significant difference in the average, overall genome
methylation (P < 0.048), but did not indicate a difference
for the oncoprotein set used in this study. And, no significant difference was found between nonsmokers and
smokers in either the genome or oncoprotein gene
methylation levels for the LUAD and HNSC datasets.

Discussion
Specific cancer mutations have represented distinctions
between nonsmoker and smoker cancers in previous studies (Albrecht and Theron 1988; Kondo et al. 1992), but
this is the first direct, confirmation of an increased overall
mutation rate in lung cancer that is attributed to smoking. Furthermore, the data above represent the first indication of a distinction in the number of CPCR mutations
in lung and head and neck cancers, between nonsmoker
and smoker cancers. Both of the preceding results are
likely representative of a significant stochastic process of

smoking-dependent mutagenesis, keeping in mind that
CPCR coding regions are relatively large and thus represent large mutagen targets.
The above work also indicates that the significant difference in CPCR mutations, between nonsmokers and smokers, leads to more deleterious amino acid substitutions
among the smoker CPCR set. Because CPCR mutations
are likely to have a dominant-negative impact, consistent
with their role in the formation of, and potential corruption of multimeric (polymer) cytoskeletal-related structures, including the extracellular matrix, the increase in
deleterious mutations may represent a proportional
increase in the CPCR dysfunction in smoker cancers. The
role of cytoskeleton and ECM dysfunction in cancer progression can be controversial, in that some reports indicate
a requirement for cytoskeletal function for migration and
other reports indicate a general association of dysfunction
with metastasis and tumor aggressiveness (Pollack et al.
1968, 1980; Vogel et al. 1973; Kopelovich et al. 1977;
Brinkley et al. 1980; Verderame et al. 1980; Chen et al.
1983; Zachary et al. 1986; Pokorna et al. 1994; Narumiya
et al. 2009; Nurnberg et al. 2011; Carlier et al. 2013; Guo
et al. 2013; Bear and Haugh 2014; Wang et al. 2014; Parry
and Blanck 2016). This issue will not be settled here, but
one possibility is that a certain level or type of cytoskeletal
disruption remains consistent with, or even favors
invadopodia formation and cell migration, while a distinct
type of cytoskeletal disruption favors tissue detachment
and circulation of tumor cells throughout the body.
While oncogene and tumor suppressor gene mutation
rates distinguish nonsmokers and smokers in the LUAD
dataset, no other TCGA dataset is represented by this distinction. Overall mutation rates and CPCR mutation rates
distinguish nonsmoker and smoker HNSC groups, consistent with the large target afforded by the CPCR set that
presumably registers the overall mutation rate. These data
raise the question of whether nonsmoker and smoker
cancers have phenotypic and clinical differences based on
the greater level of CPCR mutations. These data also raise
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Table 4. Methylation beta averages for the top five available barcodes with the highest mutation burdens for smokers and nonsmokers in all four cancer sets for the overall genome methylation
and the oncoprotein dataset (detailed in the SOM file labeled,
“SOM Table 4, source file”).

LUAD

Smoker

Nonsmoker

HNSC

Smoker

Nonsmoker

BLCA

Smoker

Nonsmoker

PAAD

Smoker

Nonsmoker

TCGA-44-2656
TCGA-44-2659
TCGA-44-2668
TCGA-44-5644
TCGA-44-7670
TCGA-44-2665
TCGA-50-5066
TCGA-86-8279
TCGA-86-8585
TCGA-86-8672
TCGA-CN-4723
TCGA-CR-7402
TCGA-CV-6961
TCGA-CV-7245
TCGA-D6-6516
TCGA-BA-5152
TCGA-BB-4223
TCGA-CR-6472
TCGA-CR-6481
TCGA-CV-7252
TCGA-BT-A2LB
TCGA-DKA1AC
TCGA-DK-A6AW
TCGA-FD-A6TC
TCGA-ZF-A9RC
TCGA-DK-A3WW
TCGA-G2-A2EO
TCGA-K4-A6FZ
TCGA-MV-A51V
TCGA-SY-A9G5
TCGA-3A-A919
TCGA-H6-8124
TCGA-LB-A7SX
TCGA-OE-A75W
TCGA-PZ-A5RE
TCGA-2L-AAQJ
TCGA-3A-A9J0
TCGA-FB-AAPU
TCGA-HV-A7OP
TCGA-IB-7652

Total
beta
P-value

Oncoprotein
beta P-value

0.1202

0.0827

0.5145

0.2851

0.0081

0.0100

0.0476

0.0622
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several related questions. Certain studies have indicated
that higher cancer mutation rates indicate greater sensitivity to mutagenic drugs. This result could be due to
reduced DNA repair functions or due to “weakened” cells
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unable to tolerate additional genotoxicity. Are there distinctions between nonsmoker and smoker responses to
mutagenic chemotherapy? In addition, the above data
would indicate that clinical differences dependent on
oncogene or tumor suppressor gene mutations would not
be apparent for nonsmoker and smoker cancers.
There are many possible explanations for cancer development besides mutations, including copy number variation, partial deletions, and epigenetic processes. In
particular, certain studies have associated DNA methylation, or lack of methylation with cancers arising from
tobacco use (Philibert et al. 2014; Bjaanaes et al. 2016).
Data presented here do indicate an alternative explanation
for a lack of mutation-based distinction of nonsmoker
and smoker cancers: demethylation of oncogenes in
BLCA. These data are consistent with the possibility that
nonsmoker and smoker pancreatic cancers are not distinguishable on the basis of mutation frequency.
Finally, the above data indicate that lung cancer arising
after cessation of smoking represented reduced levels of
overall mutations, the first such indication, although
specific gene mutation profiles are known to be different
in cancers arising years after smoking cessation (Bernardini et al. 2001; Ha and Califano 2002). The reduced
number of mutations in smoking-cessation cancers raises
interesting questions about the change in the mutation
profiles of the lung cells over the years since the use of
tobacco. For example, are the heavily mutated cells indeed
weakened and therefore lost to genotoxicity? Is there a
natural rate of turnover in the cells that are sources of
lung cancer, such that smoking-cessation cancers are
essentially the result of the same processes that lead to
low mutation burdened, nonsmoker lung cancers?
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